Journal article icon

Journal article

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease

Abstract:

This was a Phase 2 study (NCT02015793) to evaluate the pharmacokinetics, safety, and efficacy of adalimumab in Chinese patients with Crohn's disease (CD).Thirty, adult Chinese patients with CD (CD Activity Index [CDAI] 220-450; high-sensitivity [hs]-C-reactive protein [CRP] ≥3 mg/L) received double-blind adalimumab 160/80 mg or 80/40 mg at weeks 0/2, followed by 40 mg at weeks 4 and 6. An open-label extension period occurred from weeks 8-26; patients received 40 mg adalimumab every other week...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's version

Actions


Access Document


Files:
Publisher copy:
10.5217/ir.2016.14.2.152

Authors


Expand authors...
Publisher:
Korean Association for the Study of Intestinal Diseases Publisher's website
Journal:
Intestinal research Journal website
Volume:
14
Issue:
2
Pages:
152-163
Publication date:
2016-04-27
DOI:
EISSN:
2288-1956
ISSN:
1598-9100
URN:
uuid:8a061575-aee5-4587-b991-7eac7c491127
Source identifiers:
623104
Local pid:
pubs:623104

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP